Humana Inc. (NYSE:HUM) Shares Bought by Fidelis Capital Partners LLC

Fidelis Capital Partners LLC boosted its holdings in shares of Humana Inc. (NYSE:HUM) by 16.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,002 shares of the insurance provider’s stock after buying an additional 145 shares during the period. Fidelis Capital Partners LLC’s holdings in Humana were worth $459,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. Rakuten Securities Inc. acquired a new position in Humana during the 4th quarter valued at about $25,000. Sunbelt Securities Inc. acquired a new position in shares of Humana in the first quarter valued at about $28,000. Gradient Investments LLC increased its holdings in shares of Humana by 200.0% in the fourth quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock valued at $27,000 after purchasing an additional 40 shares during the period. Nvwm LLC increased its holdings in shares of Humana by 41.0% in the third quarter. Nvwm LLC now owns 86 shares of the insurance provider’s stock valued at $42,000 after purchasing an additional 25 shares during the period. Finally, Operose Advisors LLC acquired a new position in shares of Humana in the third quarter valued at about $56,000. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Stock Performance

NYSE HUM opened at $328.33 on Friday. The company has a market cap of $39.61 billion, a PE ratio of 16.57, a price-to-earnings-growth ratio of 1.90 and a beta of 0.45. The stock’s 50 day simple moving average is $330.40 and its 200-day simple moving average is $400.99. Humana Inc. has a 1-year low of $299.23 and a 1-year high of $541.21. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.59 and a quick ratio of 1.59.

Humana (NYSE:HUM) last posted its quarterly earnings results on Thursday, January 25th. The insurance provider reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.76 by ($0.87). Humana had a net margin of 2.34% and a return on equity of 19.44%. The company had revenue of $26.46 billion during the quarter, compared to analyst estimates of $25.47 billion. During the same period in the prior year, the business posted $1.62 EPS. Humana’s revenue for the quarter was up 17.9% compared to the same quarter last year. As a group, equities research analysts anticipate that Humana Inc. will post 16.06 EPS for the current fiscal year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be issued a $0.885 dividend. The ex-dividend date is Friday, June 28th. This represents a $3.54 annualized dividend and a dividend yield of 1.08%. Humana’s dividend payout ratio is presently 17.86%.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on HUM shares. StockNews.com downgraded Humana from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 26th. The Goldman Sachs Group lowered their target price on Humana from $450.00 to $385.00 and set a “buy” rating on the stock in a research note on Wednesday, April 3rd. Wells Fargo & Company lowered their target price on Humana from $413.00 to $350.00 and set an “overweight” rating on the stock in a research note on Monday, April 8th. Truist Financial restated a “hold” rating and issued a $550.00 target price on shares of Humana in a research note on Friday, January 19th. Finally, TheStreet downgraded Humana from a “b” rating to a “c+” rating in a research report on Monday, January 8th. Eleven analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, Humana has a consensus rating of “Hold” and a consensus price target of $465.42.

Insider Activity at Humana

In related news, Director Jorge S. Mesquita purchased 545 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The stock was purchased at an average price of $367.09 per share, with a total value of $200,064.05. Following the completion of the acquisition, the director now owns 2,578 shares in the company, valued at $946,358.02. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.32% of the company’s stock.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.